Neurocrine Biosciences (NBIX) reported 515.3millioninrevenueforthequarterendedMarch2024,representingayear−over−yearincreaseof22.60.42 for the same period compares to -0.79ayearago.ThereportedrevenuecomparestotheZacksConsensusEstimateof512.21 million, representing a surprise of +0.60%. The company delivered an EPS surprise of -59.62%, with the consensus EPS estimate being $1.04.While investors closely watch year-over-year changes in headline numbers -- revenue and ea ...